Video

Dr. Ueno on Liquid Biopsy

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.

It is difficult to subject patients to multiple traditional biopsies due to the potential risks and burden of the patient, explains Ueno.

Liquid biopsies, which use circulating tumor cells (CTCs) and fragments of tumor DNA, provide a bigger picture of biological changes at the metastatic site, without using invasive techniques.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center